Intrinsic coagulation activation and the risk of arterial thrombosis in young women: Results from the risk of arterial thrombosis in relation to oral contraceptives (RATIO) case-control study

Circulation

Volumn 122, Issue 18, 2010, Pages 1854-1861

  Siegerink, B ^a   Govers Riemslag, J W P ^b   Rosendaal, F R ^a   Ten Cate, H ^b   Algra, A ^a,c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

activation; coagulation, intrinsic; thrombosis, arterial; women

Indexed keywords

BLOOD CLOTTING FACTOR 11A; BLOOD CLOTTING FACTOR 11A ANTITRYPSIN INHIBITOR; BLOOD CLOTTING FACTOR 11A COMPLEMENT COMPONENT C1S INHIBITOR; BLOOD CLOTTING FACTOR 12A; BLOOD CLOTTING FACTOR 12A COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C1S INHIBITOR; KALLIKREIN; KALLIKREIN COMPLEMENT COMPONENT C1S INHIBITOR; ORAL CONTRACEPTIVE AGENT; TRYPSIN INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ARTERY THROMBOSIS; ARTICLE; BLOOD CLOTTING; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEART INFARCTION; HUMAN; INTRINSIC COAGULATION ACTIVATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ADOLESCENT; ADULT; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; BRADYKININ; CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL; FACTOR XI; FACTOR XII; FEMALE; HUMANS; KALLIKREINS; KININOGENS; MIDDLE AGED; MYOCARDIAL INFARCTION; PREKALLIKREIN; RISK FACTORS; STROKE; THROMBOSIS; YOUNG ADULT;

EID: 78349308080     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.110.943738     Document Type: Article

References (24)

1. World Health Organization. The Top 10 Causes of Death: Fact Sheet 310. Geneva, Switzerland: World Health Organization; 2008.
2. Kaplan AP, Silverberg M. The coagulation-kinin pathway of human plasma. Blood. 1987;70:1-15.
3. Farsetti A, Misiti S, Citarella F, Felici A, Andreoli M, Fantoni A, Sacchi A, Pontecorvi A. Molecular basis of estrogen regulation of Hageman factor XII gene expression. Endocrinology. 1995;136: 5076-5083.
4. van Dieijen G, Tans G, Rosing J, Hemker HC. The role of phospholipid and factor VIIIa in the activation of bovine factor X. J Biol Chem. 1981;256:3433-3442.
5. Radcliffe R, Bagdasarian A, Colman R, Nemerson Y. Activation of bovine factor VII by hageman factor fragments. Blood. 1977;50: 611-617.
6. Colman RW, Schmaier AH. Contact system: a vascular biology mod-ulator with anticoagulant, profibrinolytic, antiadhesive, and proinflam-matory attributes. Blood. 1997;90:3819-3843.
7. Schmaier AH. Assembly, activation, and physiologic influence of the plasma kallikrein/kinin system. Int Immunopharmacol. 2008;8: 161-165.
8. Renne T, Pozgajova M, Gruner S, Schuh K, Pauer HU, Burfeind P, Gailani D, Nieswandt B. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med. 2005;202:271-281.
9. Gailani D, Renne T. Intrinsic pathway of coagulation and arterial thrombosis. Arterioscler Thromb Vasc Biol. 2007;27:2507-2513.
10. Salomon O, Steinberg DM, Dardik R, Rosenberg N, Zivelin A, Tamarin I, Ravid B, Berliner S, Seligsohn U. Inherited factor XI deficiency confers no protection against acute myocardial infarction. J Thromb Haemost. 2003;1:658-661.
11. Salomon O, Steinberg DM, Koren-Morag N, Tanne D, Seligsohn U. Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. Blood. 2008;111:4113-4117.
12. Doggen CJ, Rosendaal FR, Meijers JC. Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: Opposite and synergistic effects of factors XI and XII. Blood. 2006;108: 4045-4051.
13. Endler G, Marsik C, Jilma B, Schickbauer T, Quehenberger P, Mannhalter C. Evidence of a U-shaped association between factor XII activity and overall survival. J Thromb Haemost. 2007;5: 1143-1148.
14. Govers-Riemslag JW, Smid M, Cooper JA, Bauer KA, Rosenberg RD, Hack CE, Hamulyak K, Spronk HM, Miller GJ, Ten CH. The plasma kallikrein-kinin system and risk of cardiovascular disease in men. J Thromb Haemost. 2007;5:1896-1903.
15. Cleuren ACA, van der Linden IK, de Visser YP, Wagenaar GTM, Reitsma PH, van Vlijmen BJM. 17alpha-Ethinylestradiol rapidly alters transcript levels of murine coagulation genes via estrogen receptor alpha. J Thromb Haemost. 2010;8:1838-1846.
16. Kemmeren JM, Tanis BC, van den Bosch MA, Bollen EL, Helmerhorst FM, van der Graaf Y, Rosendaal FR, Algra A. Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke. Stroke. 2002;33: 1202-1208.
17. Tanis BC, van den Bosch MA, Kemmeren JM, Manger Cats V, Helmerhorst FM, Algra A, van der Graaf Y, Rosendaal FR. Oral contra-ceptives and the risk of myocardial infarction. N Engl J Med. 2001;345: 1787-1793.
18. van den Bosch MA, Kemmeren JM, Tanis BC, Mali WP, Helmerhorst FM, Rosendaal FR, Algra A, van der Graaf Y. The RATIO study: oral contraceptives and the risk ofperipheral arterial disease in young women. J Thromb Haemost. 2003;1:439-444.
19. Pruissen DM, Slooter AJ, Rosendaal FR, van der Graaf Y, Algra A. Coagulation factor XIII gene variation, oral contraceptives, and risk of ischemic stroke. Blood. 2008;111:1282-1286.
20. Nuijens JH, Huijbregts CC, Eerenberg-Belmer AJ, Abbink JJ, Strack van Schijndel RJ, Felt-Bersma RJ, Thijs LG, Hack CE. Quantification of plasma factor XIIa-Cl(-)-inhibitor and kallikrein-Cl(-)-inhibitor com-plexes in sepsis. Blood. 1988;72:1841-1848.
21. Nuijens JH, Huijbregts CC, Eerenberg-Belmer AJ, Meijers JC, Bouma BN, Hack CE. Activation of the contact system of coagulation by a monoclonal antibody directed against a neodeterminant in the heavy chain region of human coagulation factor XII (Hageman factor). J Biol Chem. 1989;264:12941-12949.
22. Wuillemin WA, Minnema M, Meijers JC, Roem D, Eerenberg AJ, Nuijens JH, Ten CH, Hack CE. Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: major role for C1-inhibitor. Blood. 1995;85:1517-1526.
23. Nuijens JH, Huijbregts CC, van Mierlo GM, Hack CE. Inactivation of C-1 inhibitor by proteases: demonstration by a monoclonal antibody of a neode-terminant on inactivated, non-complexed C-1 inhibitor. Immunology. 1987; 61:387-389.
24. Abbink JJ, Kamp AM, Swaak AJ, Hack CE. Production of monoclonal antibodies against inactivated alpha 1-antitrypsin: cross-reactivity with complexed alpha 1-antitrypsin and application in an assay to determine inactivated and complexed alpha 1-antitrypsin in biological fluids. J Immunol Methods. 1991;143:197-208.